Metraipolis › archive › dc_cfbdbcd1e252

Inactivation of NF-κB and MAPKs confers the potent therapeutic effect of carboxyamidotriazole on Blau syndrome — Europe PMC PMID:41888882

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41888882
DOI: 10.1186/s13075-[numero omesso]-2
License (as archived): solo-consultazione
Archived: 2026-10-07T22:04:08.467Z
SHA-256 of the archived text: 6691f2ed786b4d0c0b84dd8df21b80817256b3b306c2728c11678fb4dca1d651
Stable URL of this page: https://metraipolis.com/documento/dc_cfbdbcd1e252

How to cite

Inactivation of NF-κB and MAPKs confers the potent therapeutic effect of carboxyamidotriazole on Blau syndrome — Europe PMC PMID:41888882 — Europe PMC (en), https://europepmc.org/article/MED/41888882 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_cfbdbcd1e252 (Metraipolis archive dc_cfbdbcd1e252, sha256 6691f2ed786b4d0c0b84dd8df21b80817256b3b306c2728c11678fb4dca1d651)

BibTeX

@misc{dccfbdbcd1e252,
  title = {Inactivation of NF-κB and MAPKs confers the potent therapeutic effect of carboxyamidotriazole on Blau syndrome — Europe PMC PMID:41888882},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41888882},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_cfbdbcd1e252; sha256 6691f2ed786b4d0c0b84dd8df21b80817256b3b306c2728c11678fb4dca1d651},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41888882. Agents can read the archived copy with the MCP tool read_document.